Fidelity Advisor Biotechnology Fund Class A (FBTAX) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Fidelity Advisor Biotechnology Fund Class A (FBTAX) trades at $52.27. Fidelity Advisor Biotechnology Fund Class A (FBTAX) is a non-diversified fund focused on capital appreciation through investments in biotechnology companies. Market cap: $2.55B, Sector: Financial services.
Price as of Aug 20, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for FBTAX: FBTAX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates FBTAX against Financial Services peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on FBTAX.
How is this calculated? →Fidelity Advisor Biotechnology Fund Class A (FBTAX) Financial Services Profile
Fidelity Advisor Biotechnology Fund Class A (FBTAX) seeks capital appreciation by investing at least 80% of its assets in biotechnology companies. The fund utilizes fundamental analysis to select domestic and foreign issuers, distinguishing itself through a non-diversified approach within the asset management sector.
What Is the Investment Thesis for FBTAX?
Fidelity Advisor Biotechnology Fund Class A (FBTAX) presents an investment opportunity centered on the growth potential of the biotechnology sector. With a beta of 0.90, the fund exhibits slightly lower volatility compared to the broader market. The fund's strategy of concentrating investments in biotechnology companies could lead to substantial returns if the sector continues to innovate and expand. Key value drivers include advancements in biotechnology, regulatory approvals of new drugs and therapies, and increasing healthcare spending. However, the fund's non-diversified nature and sector-specific focus also introduce risks, such as regulatory setbacks, clinical trial failures, and market downturns affecting the biotechnology industry. While FBTAX does not offer a dividend yield, its potential for capital appreciation remains the primary focus for investors.
Based on FMP financials and quantitative analysis
FBTAX Key Highlights
The fund has a market capitalization of $2.55B, reflecting its significant presence in the biotechnology investment space.
- FBTAX invests at least 80% of its assets in biotechnology companies, demonstrating a strong commitment to the sector.
- The fund's beta of 0.90 indicates a slightly lower volatility compared to the overall market.
- FBTAX employs fundamental analysis to select investments, focusing on financial condition, industry position, and market conditions.
- As a non-diversified fund, FBTAX concentrates its investments, potentially leading to higher returns but also greater risk.
Who Are FBTAX's Competitors?
FBTAX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AOM iShares Core 40/60 Moderate Allocation ETF | $49.99 | +0.66% | $1.82B | 47 |
| DGS WisdomTree Emerging Markets SmallCap Dividend Fund | $63.43 | +1.13% | $1.84B | 47 |
| FDVIX Fidelity Advisor Diversified International Fund | $32.47 | -0.18% | $1.86B | 44 |
| FHKAX Fidelity Advisor China Region Fund Class A | $70.97 | -0.64% | $2.87B | — |
| FITIX Fidelity Advisor Mid Cap II Fund Class M | $27.47 | -0.18% | $1.78B | 44 |
| GCMG GCM Grosvenor Inc. | $13.78 | +0.88% | $2.58B | 95 |
| FSENX Fidelity Select Portfolios - Energy Portfolio | $92.14 | -0.38% | $2.65B | 69 |
| APAM Artisan Partners Asset Management Inc. | $42.50 | +1.99% | $3.02B | 70 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are FBTAX's Key Strengths?
Strong focus on the high-growth biotechnology sector.
- Experienced investment team with expertise in fundamental analysis.
- Established brand and reputation of Fidelity Investments.
- Access to global investment opportunities.
What Are FBTAX's Weaknesses?
Non-diversified approach increases risk.
- High dependence on the performance of the biotechnology sector.
- Subject to regulatory and clinical trial risks.
- No dividend yield.
What Could Drive FBTAX Stock Higher?
Clinical trial results for key portfolio companies in Q2 2026 may drive stock prices.
- Regulatory approvals for new drugs and therapies within portfolio holdings can lead to significant gains.
- Increasing healthcare spending and investment in biotechnology will support sector growth.
What Are the Key Risks for FBTAX?
Regulatory setbacks and clinical trial failures can negatively impact portfolio holdings.
- Market downturns affecting the biotechnology sector can lead to decreased asset values.
- Competition from other biotechnology-focused funds may limit growth.
- Changes in healthcare policies and reimbursement rates can affect profitability.
What Are the Growth Opportunities for FBTAX?
- Advancements in Gene Therapy: The gene therapy market is projected to reach $13 billion by 2030, driven by breakthroughs in treating genetic disorders. FBTAX can capitalize on this growth by investing in companies developing innovative gene therapies, potentially leading to significant returns as these therapies gain regulatory approval and market adoption. The timeline for realizing these gains depends on clinical trial outcomes and regulatory processes, but the long-term potential is substantial.
- Increasing Healthcare Spending: Global healthcare spending is expected to continue its upward trajectory, reaching $10 trillion by 2028. This trend provides a favorable backdrop for the biotechnology industry, as increased healthcare budgets support the development and adoption of new biotechnological products and services. FBTAX can benefit from this trend by investing in companies that are well-positioned to capture a share of the growing healthcare market, particularly those focused on innovative and cost-effective solutions.
- FBTAX can leverage this trend by investing in companies that are developing personalized medicine solutions, such as targeted therapies and diagnostic tools. These investments can provide significant growth opportunities as personalized medicine becomes more integrated into healthcare practices.
- Regulatory Approvals of New Drugs: The biotechnology industry is heavily reliant on regulatory approvals for new drugs and therapies. Successful clinical trials and subsequent regulatory approvals can lead to substantial increases in the value of biotechnology companies. FBTAX can benefit from this dynamic by investing in companies with promising drug candidates in their pipelines, particularly those targeting unmet medical needs. The timeline for realizing these gains depends on the clinical trial and regulatory review processes.
- Strategic Partnerships and Acquisitions: The biotechnology industry is characterized by frequent strategic partnerships and acquisitions, as larger companies seek to acquire innovative technologies and products. FBTAX can benefit from this trend by investing in smaller biotechnology companies that are attractive acquisition targets. These investments can provide significant returns if the companies are acquired at a premium, creating value for FBTAX's investors.
What Are FBTAX's Competitive Advantages?
- Established brand and reputation of Fidelity Investments.
- Expertise in fundamental analysis of biotechnology companies.
- Access to a global network of research and investment professionals.
What Does FBTAX Do?
Fidelity Advisor Biotechnology Fund Class A (FBTAX) is an actively managed, non-diversified fund within the Fidelity Investments family, dedicated to seeking capital appreciation. The fund was established to provide investors with exposure to the high-growth potential of the biotechnology sector. FBTAX invests primarily in the common stocks of companies that are principally engaged in the research, development, manufacture, and distribution of biotechnological products, services, and processes. This includes companies that significantly benefit from scientific and technological advances in biotechnology. The fund's investment strategy involves fundamental analysis, where factors such as the issuer's financial condition, industry position, and overall market and economic conditions are carefully evaluated to select investments. FBTAX invests in both domestic and foreign issuers, providing a global perspective on the biotechnology industry. The fund’s non-diversified status means it can concentrate its investments in a smaller number of companies, potentially leading to higher returns but also greater volatility. As of 2026, the fund manages approximately $1.52 billion in assets.
What Products and Services Does FBTAX Offer?
- Invests primarily in common stocks of biotechnology companies.
- Focuses on companies engaged in the research, development, manufacture, and distribution of biotechnological products, services, and processes.
- Utilizes fundamental analysis to select investments.
- Invests in both domestic and foreign issuers.
- Operates as a non-diversified fund, concentrating investments in a smaller number of companies.
- Seeks capital appreciation for its investors.
How Does FBTAX Make Money?
- Generates revenue through management fees charged as a percentage of assets under management (AUM).
- Aims to increase AUM by attracting new investors and achieving positive investment returns.
- Reinvests earnings to support further growth and investment opportunities.
What Industry Does FBTAX Operate In?
Fidelity Advisor Biotechnology Fund Class A (FBTAX) operates within the asset management industry, specifically targeting the biotechnology sector. The biotechnology industry is characterized by rapid innovation, high growth potential, and significant regulatory oversight. Market trends include increasing investments in personalized medicine, gene therapy, and other advanced biotechnologies. The competitive landscape includes other biotechnology-focused funds and broader healthcare investment vehicles. FBTAX distinguishes itself through its non-diversified approach and focus on fundamental analysis to identify promising biotechnology companies.
Who Are FBTAX's Key Customers?
- Individual investors seeking exposure to the biotechnology sector.
- Institutional investors looking for specialized investment strategies.
- Financial advisors seeking investment options for their clients.
Financial Health
Fidelity Advisor Biotechnology Fund Class A's Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 12.97 places it in the safe zone, indicating low near-term bankruptcy risk.
FBTAX Financials
Bull Case vs Bear Case
Bull Case
- Strong focus on the high-growth biotechnology sector.
- Experienced investment team with expertise in fundamental analysis.
- Established brand and reputation of Fidelity Investments.
- Access to global investment opportunities.
Bear Case
- Non-diversified approach increases risk.
- High dependence on the performance of the biotechnology sector.
- Subject to regulatory and clinical trial risks.
- No dividend yield.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
FBTAX Latest News
No recent news available for FBTAX.
FBTAX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for FBTAX.
Price Targets
Wall Street price target analysis for FBTAX.
FBTAX MoonshotScore
What does this score mean?
The MoonshotScore rates FBTAX 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Fidelity Advisor Biotechnology Fund Class A Financial Services Stock: Key Questions Answered
What does Fidelity Advisor Biotechnology Fund Class A do?
Fidelity Advisor Biotechnology Fund Class A (FBTAX) is a non-diversified fund that invests primarily in the common stocks of companies engaged in the research, development, manufacture, and distribution of biotechnological products, services, and processes. The fund aims to achieve capital appreciation by focusing on companies that benefit significantly from scientific and technological advances in biotechnology.
What are the main risks for FBTAX?
The primary risks for Fidelity Advisor Biotechnology Fund Class A (FBTAX) include regulatory setbacks, clinical trial failures, and market downturns affecting the biotechnology sector. As a non-diversified fund, FBTAX is particularly vulnerable to negative news or events impacting its portfolio holdings. Changes in healthcare policies and reimbursement rates can also affect the profitability of biotechnology companies, impacting the fund's performance.
How does Fidelity Advisor Biotechnology Fund Class A generate revenue?
Fidelity Advisor Biotechnology Fund Class A (FBTAX) generates revenue primarily through management fees, which are charged as a percentage of the fund's assets under management (AUM). These fees compensate Fidelity for its expertise in selecting and managing the fund's investments. The fund's ability to attract new investors and achieve positive investment returns directly impacts its AUM and, consequently, its revenue.
What regulatory challenges does Fidelity Advisor Biotechnology Fund Class A face?
Fidelity Advisor Biotechnology Fund Class A (FBTAX) faces regulatory challenges primarily related to the biotechnology companies it invests in. These companies are subject to stringent regulations from agencies like the FDA, which govern the approval and marketing of new drugs and therapies. Clinical trial outcomes and regulatory reviews can significantly impact the value of these companies.
What are the key factors to evaluate for FBTAX?
Evaluate FBTAX on fundamentals, analyst consensus, and risk factors. Fidelity Advisor Biotechnology Fund Class A (FBTAX) presents an investment opportunity centered on the growth potential of the biotechnology sector. Not financial advice.
How frequently does FBTAX data refresh on this page?
FBTAX's price was last updated on Aug 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven FBTAX's recent stock price performance?
Fidelity Advisor Biotechnology Fund Class A (FBTAX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong focus on the high-growth biotechnology sector. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider FBTAX overvalued or undervalued right now?
Fidelity Advisor Biotechnology Fund Class A (FBTAX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending for FBTAX, limiting the availability of analyst consensus and forward-looking estimates.
- The information provided is based on available data and may be subject to change.